SNHG6

Summary

SNHG6 (small nucleolar RNA host gene 6, HGNC:32965) is a long non-coding RNA gene on chromosome 8q13.1.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32965
Approved symbol	SNHG6
Name	small nucleolar RNA host gene 6
Location	8q13.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	U87HG, HBII-276HG, NCRNA00058
Ensembl gene	ENSG00000245910
Ensembl biotype	lncRNA
OMIM	612215
Entrez	641638
RNAcentral	URS0000CCE10C — lncRNA, 727 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 29 lncRNA, 1 retained_intron

ENST00000520348, ENST00000520619, ENST00000520944, ENST00000521127, ENST00000521399, ENST00000686474, ENST00000689720, ENST00000693345, ENST00000820839, ENST00000820840, ENST00000820841, ENST00000820842, ENST00000820843, ENST00000820844, ENST00000820845, ENST00000820846, ENST00000820847, ENST00000820848, ENST00000820849, ENST00000820850, ENST00000820851, ENST00000820852, ENST00000820853, ENST00000820854, ENST00000820855, ENST00000820856, ENST00000820857, ENST00000820858, ENST00000820859, ENST00000820860

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000520348 — 4 exons

Exon	Start	End
ENSE00001977178	66922614	66922725
ENSE00003926553	66922324	66922385
ENSE00004227155	66925437	66925549
ENSE00004227174	66921927	66922114

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 99.77.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 213.2476 / max 1921.5526, expressed in 1827 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
93426	213.2476	1827

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	99.77	gold quality
upper arm skin	UBERON:0004263	99.73	gold quality
thymus	UBERON:0002370	99.72	gold quality
tibialis anterior	UBERON:0001385	99.67	gold quality
germinal epithelium of ovary	UBERON:0001304	99.58	gold quality
cartilage tissue	UBERON:0002418	99.53	gold quality
epithelial cell of pancreas	CL:0000083	99.48	gold quality
ganglionic eminence	UBERON:0004023	99.48	gold quality
quadriceps femoris	UBERON:0001377	99.47	gold quality
pigmented layer of retina	UBERON:0001782	99.47	gold quality
medial globus pallidus	UBERON:0002477	99.46	gold quality
deltoid	UBERON:0001476	99.44	gold quality
globus pallidus	UBERON:0001875	99.43	gold quality
vastus lateralis	UBERON:0001379	99.42	gold quality
cortical plate	UBERON:0005343	99.42	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.40	gold quality
biceps brachii	UBERON:0001507	99.39	gold quality
spinal cord	UBERON:0002240	99.37	gold quality
left ovary	UBERON:0002119	99.36	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.36	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.36	gold quality
inferior vagus X ganglion	UBERON:0005363	99.35	gold quality
medulla oblongata	UBERON:0001896	99.33	gold quality
ventricular zone	UBERON:0003053	99.33	gold quality
urethra	UBERON:0000057	99.32	gold quality
mucosa of stomach	UBERON:0001199	99.32	gold quality
layer of synovial tissue	UBERON:0007616	99.31	gold quality
pons	UBERON:0000988	99.30	gold quality
superficial temporal artery	UBERON:0001614	99.29	gold quality
saphenous vein	UBERON:0007318	99.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	16.67

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• High SNHG6 expression is associated with the progression of hepatocellular carcinoma. (PMID:27530352)
• Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma, promoting tumor growth and metastasis. (PMID:27702662)
• The analyses showed that SNHG6 is among the lncRNAs with distinctive dysregulation of expression and copy number variation in hepatocellular carcinoma tumors compared with normal tissues (PMID:28508329)
• SNHG6 acted as an oncogene in gastric cancer cells through regulating miR-101-3p/ZEB1 at a post-transcriptional level and silencing expression at a transcriptional level by recruiting enhancer of zeste homolog 2 (EZH2) to the promoter of p27. (PMID:28683446)
• SNHG6 knockdown by siRNA could inhibit cell proliferation, cell cycle progression, and induce apoptosis (PMID:29506878)
• p21 was involved in glioma cell proliferation after SNHG6 was downregulated. (PMID:29579705)
• Our study provides novel insights into the functions of lncRNA SNHG6/miR-101-3p axis in the tumorigenesis of glioma (PMID:29799357)
• SNHG6 promoted expression of MAT2A by suppressing direct binding of miR-1297 to the MAT2A 3’UTR. (PMID:29844127)
• High SNHG6 expression is associated with gastric cancer. (PMID:30031062)
• SNHG6 could promote cell proliferation via a direct suppression of p21 expression in colorectal cancer cells and repressed p21 transcription through recruiting EZH2 to the p21 promoter in colorectal cancer cells. (PMID:30157475)
• our findings reveal that SNHG6 may act as an oncogenic lncRNA in human lung adenocarcinoma carcinogenesis by regulating the miR-26a-5p/E2F7 axis. (PMID:30257360)
• SNHG6 was highly expressed in breast cancer tissues and cell lines, which was associated with poorer clinicopathologic features. (PMID:30522015)
• up-regulated SNHG6 was significantly associated with tumor progression and was an independent prognostic factor in renal cell carcinoma (RCC). (PMID:30575902)
• This study revealed that SNHG6 expression was upregulated in colorectal cancer tissues and cells. High expression of SNHG6 was associated with tumor progression and poor survival. SNHG6 promoted colorectal cancer cell growth and metastasis by acting as a molecular sponge to regulate EZH2 and its targets. These data suggest that SNHG6 may be a promising biomarker and a novel therapeutic target of colorectal cancer. (PMID:30626446)
• This gene may play an oncogenic role in colorectal cancer cells by activating TGF-beta/Smad signaling pathway via targeting of UPF1 and inducing Epithelial-Mesenchymal Transition via regulating ZEB1. (PMID:30662328)
• lncRNA SNHG6 is involved in breast cancer development and may be considered as a potential biomarker for the diagnosis, prognosis and treatment of breast cancer. (PMID:30826970)
• Bioinformatics analysis revealed that SNHG6-interacting genes were associated with translation, nuclear-transcribed mRNA catabolic process, ribosomal RNA processing and mRNA splicing. (PMID:30911973)
• Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma. (PMID:31119871)
• SNHG6 is an oncogene of WT development by targeting miR-15a (PMID:31257923)
• Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression. (PMID:31258024)
• These results suggested that SNHG6 may directly suppress ETS1, which may be one of potential mechanisms through which it inhibits the viability and proliferation of colorectal cancer cells, and it provides novel insight into the carcinogenesis of colorectal cancer. (PMID:31322251)
• SNHG6 could regulate the progression of CRC via modulating the expression levels of miR-101-3p and the activity of Wnt/beta-catenin signaling. (PMID:31533634)
• Long Noncoding RNA SNHG6 promotes hepatocellular carcinoma (HCC) cell proliferation via competitively binding let-7c-5p in hepatocellular carcinoma. (PMID:31563323)
• Meta-analysis of 1,535 patients from eighteen studies showed high expression level of SNHG6 was correlated with more advanced clinicopathological features and poor prognosis. (PMID:31710436)
• Long non-coding RNA SNHG6 promotes the growth and invasion of non-small cell lung cancer by downregulating miR-101-3p. (PMID:32147945)
• Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis. (PMID:32202941)
• LncRNA SNHG6 plays an oncogenic role in colorectal cancer and can be used as a prognostic biomarker for solid tumors. (PMID:32239696)
• Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis. (PMID:32321469)
• SPI1-induced upregulation of lncRNA SNHG6 promotes non-small cell lung cancer via miR-485-3p/VPS45 axis. (PMID:32590190)
• LncRNA SNHG6 promotes LMO3 expression by sponging miR-543 in glioma. (PMID:32613482)
• NCBP3/SNHG6 inhibits GBX2 transcription in a histone modification manner to facilitate the malignant biological behaviour of glioma cells. (PMID:32618493)
• LncRNA SNHG6 regulating Hedgehog signaling pathway and affecting the biological function of gallbladder carcinoma cells through targeting miR-26b-5p. (PMID:32744686)
• Long non-coding RNA SNHG6 increases JAK2 expression by targeting the miR-181 family to promote colorectal cancer cell proliferation. (PMID:32840014)
• LncRNA SNHG6 Induces Epithelial-Mesenchymal Transition of Pituitary Adenoma Via Suppressing MiR-944. (PMID:32935999)
• Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1alpha in clear cell renal cell carcinoma. (PMID:33150667)
• SP1-induced long non-coding RNA SNHG6 facilitates the carcinogenesis of chondrosarcoma through inhibiting KLF6 by recruiting EZH2. (PMID:33431838)
• LncRNA SNHG6 accelerates nasopharyngeal carcinoma progression via modulating miR-26a-5p/ARPP19 axis. (PMID:33744438)
• LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis. (PMID:33782812)
• LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1. (PMID:33824472)
• Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients. (PMID:34147082)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.